Eisai Pharmaceuticals India

Eisai Pharmaceuticals India company information, Employees & Contact Information

Welcome to Eisai India. Eisai (pronounced 'ā-zī’) is derived from the Japanese word for 'health product' and, here at Eisai, we discover, develop and market innovative, high quality medicines throughout the world. Eisai is one of the world's leading research-based pharmaceutical companies. With operations in the U.S., Asia, Europe, Russia, India, Africa, the Middle East, Australia and it's domestic home market of Japan, Eisai employs more than 11,000 people worldwide. Eisai Pharmaceuticals India Pvt. Ltd. (Eisai India) was incorporated in October 2004, with registered office at Mumbai. Eisai Co.,Ltd was the first Japanese company to have a 100% subsidiary in Indian pharmaceutical market. Eisai India product portfolio includes prescription medicines in several therapeutic areas such as central nervous system disorders, metastatic breast cancer, benign prostrate hyperplasia , muscle spasm, vertigo, gastrointestinal disorders, diabetes and peripheral neuropathy. Eisai India has a dedicated team of well-trained 200 field force across the country under various specialties and more than 250 employees across Research and Manufacturing. We continuously work with Medical Doctors and the Healthcare professionals in India to ensure that they have updated information on our products so that they can prescribe the best products for the health care needs of their patients. Eisai India’s integrated Manufacturing and Research facility at Visakhapatnam (Vizag), Andhra Pradesh stimulates knowledge creation between teams – from those who create products through research, to those who produce - by bringing them together on one site and is supplemented by the necessary support functions. Eisai India’s Vizag facility manufactures Drug Substances (Active Pharmaceutical Ingredients-APIs), Drug Products (Oral solid dosage forms-Tablets) and carries out Developmental Research of Active Pharmaceutical Ingredients (APIs).This facility is registered as a pharmaceutical manufacturer at regulatory agencies viz USFDA, PMDA, MHRA and WHO. Research labs at Vizag facility are recognized by the Department of scientific and industrial research (DSIR). Facility also received the Certification of ISO 14001:2004 for Environment management system (EMS), OHSAS 18001 for Occupational Health and Safety Series and ISO 27001 for Information security management system from TUV SUD.

Company Details

Employees
608
Founded
-
Address
Plot # 96,97,98,124 & 126, Ramkypharma City (Sez), Parawada, Visakhapatnam,andhra Pradesh 531019,india
Phone
+91-22-28579720
Email
ei****@****i.co.in
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Visakhapatnam, Andhra Pradesh
Looking for a particular Eisai Pharmaceuticals India employee's phone or email?

Eisai Pharmaceuticals India Questions

News

Eisai to Launch “Pariet® S,” the First Proton Pump Inhibitor RX-to-OTC in Japan - Eisai Co., Ltd.

Eisai to Launch “Pariet® S,” the First Proton Pump Inhibitor RX-to-OTC in Japan Eisai Co., Ltd.

Why It Might Not Make Sense To Buy Eisai Co., Ltd. (TSE:4523) For Its Upcoming Dividend - simplywall.st

Why It Might Not Make Sense To Buy Eisai Co., Ltd. (TSE:4523) For Its Upcoming Dividend simplywall.st

Eisai to part ways with 121 employees amid new US restructuring effort - Fierce Pharma

Eisai to part ways with 121 employees amid new US restructuring effort Fierce Pharma

Eisai Co., Ltd. 2026 Q1 - Results - Earnings Call Presentation (OTCMKTS:ESALF) 2025-08-05 - Seeking Alpha

Eisai Co., Ltd. 2026 Q1 - Results - Earnings Call Presentation (OTCMKTS:ESALF) 2025-08-05 Seeking Alpha

Newron and EA Pharma (A Subsidiary of Eisai Co., Ltd.) Announce License Agreement for Evenamide in Japan and Other Asian Territories - Yahoo Finance

Newron and EA Pharma (A Subsidiary of Eisai Co., Ltd.) Announce License Agreement for Evenamide in Japan and Other Asian Territories Yahoo Finance

Eisai Limited Bolsters Canadian Operations with Major Mississauga Expansion - PR Newswire Canada

Eisai Limited Bolsters Canadian Operations with Major Mississauga Expansion PR Newswire Canada

History of Enhancing the Company's Corporate Governance - Eisai Co., Ltd.

History of Enhancing the Company's Corporate Governance Eisai Co., Ltd.

Merck, Eisai's star-crossed Keytruda-Lenvima combo misses survival goal in GI cancer trial - Fierce Pharma

Merck, Eisai's star-crossed Keytruda-Lenvima combo misses survival goal in GI cancer trial Fierce Pharma

The First 80 Years | Eisai Co., Ltd. - Eisai Co., Ltd.

The First 80 Years | Eisai Co., Ltd. Eisai Co., Ltd.

EISAI COMPLETES CONSTRUCTION OF ITS NEW INJECTION/RESEARCH BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPAN | News Release:2022 - Eisai Co., Ltd.

EISAI COMPLETES CONSTRUCTION OF ITS NEW INJECTION/RESEARCH BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPAN | News Release:2022 Eisai Co., Ltd.

Compliance and Risk Management - Eisai Co., Ltd.

Compliance and Risk Management Eisai Co., Ltd.

Initiatives for Improving Access to Medicines - Eisai Co., Ltd.

Initiatives for Improving Access to Medicines Eisai Co., Ltd.

Prevention of Environmental Pollution - Eisai Co., Ltd.

Prevention of Environmental Pollution Eisai Co., Ltd.

Production and Logistics (Demand Chain Systems) - Eisai Co., Ltd.

Production and Logistics (Demand Chain Systems) Eisai Co., Ltd.

Message from Top Management - Eisai Co., Ltd.

Message from Top Management Eisai Co., Ltd.

Dementia - Eisai Co., Ltd.

Dementia Eisai Co., Ltd.

Corporate Venture Capital - Eisai Co., Ltd.

Corporate Venture Capital Eisai Co., Ltd.

Chapter 6 Breaking into the Top 20 Worldwide - Eisai Co., Ltd.

Chapter 6 Breaking into the Top 20 Worldwide Eisai Co., Ltd.

Corporate Governance System and Features - Eisai Co., Ltd.

Corporate Governance System and Features Eisai Co., Ltd.

Alzheimer's Disease Treatment The Aricept R&D Story - Eisai Co., Ltd.

Alzheimer's Disease Treatment The Aricept R&D Story Eisai Co., Ltd.

Chapter 7 An Ambitious Leap Forward - Eisai Co., Ltd.

Chapter 7 An Ambitious Leap Forward Eisai Co., Ltd.

hhceco (the hhc Concept + ecosystem) | Innovation - Eisai Co., Ltd.

hhceco (the hhc Concept + ecosystem) | Innovation Eisai Co., Ltd.

EISAI INC.'S U.S. HEADQUARTERS EARNS THREE KEY BUILDING CERTIFICATIONS - PR Newswire

EISAI INC.'S U.S. HEADQUARTERS EARNS THREE KEY BUILDING CERTIFICATIONS PR Newswire

Eisai Inc. Reinforces Commitment to Collaboration and Innovation to Support Patients and Communities Through New U.S. Headquarters - PR Newswire

Eisai Inc. Reinforces Commitment to Collaboration and Innovation to Support Patients and Communities Through New U.S. Headquarters PR Newswire

Eisai co-establishes “Global Health Innovative Technology Fund,” Japan's first public–private partnership to eliminate infectious disease in developing countries | Research & Development for Improving Access to Medicines - Eisai Co., Ltd.

Eisai co-establishes “Global Health Innovative Technology Fund,” Japan's first public–private partnership to eliminate infectious disease in developing countries | Research & Development for Improving Access to Medicines Eisai Co., Ltd.

Eisai Inc. Opens New HQ in Nutley - New Jersey Business Magazine

Eisai Inc. Opens New HQ in Nutley New Jersey Business Magazine

WashU, Eisai form drug discovery collaboration - WashU Medicine

WashU, Eisai form drug discovery collaboration WashU Medicine

Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments - Biogen

Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments Biogen

EISAI OPENS NEW PARENTERAL FACILITY IN CHINA - Eisai Co., Ltd.

EISAI OPENS NEW PARENTERAL FACILITY IN CHINA Eisai Co., Ltd.

Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer’s Disease in Australia - Biogen

Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer’s Disease in Australia Biogen

Eisai, Biogen Alzheimer's drug could be available to some next year - Reuters

Eisai, Biogen Alzheimer's drug could be available to some next year Reuters

Shares of Japan's Eisai tumble after EU rejects Alzheimer's drug - Reuters

Shares of Japan's Eisai tumble after EU rejects Alzheimer's drug Reuters

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease - Biogen

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease Biogen

US FDA approves injectable version of Eisai-Biogen's Alzheimer's drug - Reuters

US FDA approves injectable version of Eisai-Biogen's Alzheimer's drug Reuters

Merck, Eisai discontinue late-stage study for combo cancer therapy - Reuters

Merck, Eisai discontinue late-stage study for combo cancer therapy Reuters

Eisai files for approval of Alzheimer's drug in Japan - Reuters

Eisai files for approval of Alzheimer's drug in Japan Reuters

FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease - Biogen

FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Biogen

ORAL ANTIFUNGAL AGENT NAILIN® CAPSULES 100MG TO BE LAUNCHED IN JAPAN - Eisai Co., Ltd.

ORAL ANTIFUNGAL AGENT NAILIN® CAPSULES 100MG TO BE LAUNCHED IN JAPAN Eisai Co., Ltd.

Eisai partners with Nichi-Iko in generics pact - BioPharma Dive

Eisai partners with Nichi-Iko in generics pact BioPharma Dive

Biogen and Eisai Announce FDA’s 3-Month Extension of Review Period for the Biologics License Application for Aducanumab - Biogen

Biogen and Eisai Announce FDA’s 3-Month Extension of Review Period for the Biologics License Application for Aducanumab Biogen

Eisai and Biogen Self-Injected Alzheimer Drug Wins US Approval - Bloomberg.com

Eisai and Biogen Self-Injected Alzheimer Drug Wins US Approval Bloomberg.com

Eisai to Present E7386, co-created by PRISM BioLab and Eisai, at the ESMO (European Society for Medical Oncology) Annual Meeting - PR Newswire

Eisai to Present E7386, co-created by PRISM BioLab and Eisai, at the ESMO (European Society for Medical Oncology) Annual Meeting PR Newswire

Eisai Inc announces U.S. approval for insomnia drug - Reuters

Eisai Inc announces U.S. approval for insomnia drug Reuters

Eisai Inc. Deepens Its Commitment to Alzheimer's Disease with Key Executive Appointments - PR Newswire

Eisai Inc. Deepens Its Commitment to Alzheimer's Disease with Key Executive Appointments PR Newswire

Eisai unveils 300,000 sq. ft. U.S. headquarters at Prism’s ON3 campus - RE-NJ

Eisai unveils 300,000 sq. ft. U.S. headquarters at Prism’s ON3 campus RE-NJ

Biogen and Eisai Expand Existing Collaboration Agreement to Develop and Commercialize Investigational Alzheimer’s Disease Treatments Including Phase 3 Aducanumab - Biogen

Biogen and Eisai Expand Existing Collaboration Agreement to Develop and Commercialize Investigational Alzheimer’s Disease Treatments Including Phase 3 Aducanumab Biogen

Companies in Alzheimer's race after US nod for Eisai/Biogen drug - Reuters

Companies in Alzheimer's race after US nod for Eisai/Biogen drug Reuters

Eisai, Biogen start U.S. accelerated approval for new Alzheimer's drug - Reuters

Eisai, Biogen start U.S. accelerated approval for new Alzheimer's drug Reuters

SEED Therapeutics (SEED) Enters into Strategic Research - GlobeNewswire

SEED Therapeutics (SEED) Enters into Strategic Research GlobeNewswire

/U P D A T E -- Eisai Inc./ - Yahoo Finance

/U P D A T E -- Eisai Inc./ Yahoo Finance

Eisai Inc. Opens New US Headquarters on ON3 Campus in Nutley - New Jersey Business Magazine

Eisai Inc. Opens New US Headquarters on ON3 Campus in Nutley New Jersey Business Magazine

Biogen, Eisai Alzheimer's drug lecanemab gets 'fast track' designation from FDA - Reuters

Biogen, Eisai Alzheimer's drug lecanemab gets 'fast track' designation from FDA Reuters

Eisai Stock: Leqembi Approved In EU (OTCMKTS:ESALF) - Seeking Alpha

Eisai Stock: Leqembi Approved In EU (OTCMKTS:ESALF) Seeking Alpha

Pharma brings 800 jobs back to Roche site. But Nutley, Clifton can't agree on what's next - Bergen Record

Pharma brings 800 jobs back to Roche site. But Nutley, Clifton can't agree on what's next Bergen Record

Eisai Inc. appoints new CFO - ROI-NJ

Eisai Inc. appoints new CFO ROI-NJ

Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease - Biogen

Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease Biogen

Eisai Co. Evaluates Fycompa’s Safety in New Clinical Study - TipRanks

Eisai Co. Evaluates Fycompa’s Safety in New Clinical Study TipRanks

Eisai To Shut Down H3 In Global R&D Restructuring - Citeline News & Insights

Eisai To Shut Down H3 In Global R&D Restructuring Citeline News & Insights

Eisai Co. Surpasses FY 2024 Expectations Amid Challenges - TipRanks

Eisai Co. Surpasses FY 2024 Expectations Amid Challenges TipRanks

Eisai expands direct presence in Saudi Arabia with new pharma sales subsidiary - BioSpectrum Asia

Eisai expands direct presence in Saudi Arabia with new pharma sales subsidiary BioSpectrum Asia

Simmons & Simmons advises Eisai Co., Ltd. on the sale to H.A.C. - Simmons & Simmons

Simmons & Simmons advises Eisai Co., Ltd. on the sale to H.A.C. Simmons & Simmons

Eisai to take space at Greenleigh at Crossroads in Baltimore County - Baltimore Sun

Eisai to take space at Greenleigh at Crossroads in Baltimore County Baltimore Sun

EU negative on approving Eisai’s Alzheimer’s drug lecanemab - arabnews.jp

EU negative on approving Eisai’s Alzheimer’s drug lecanemab arabnews.jp

Pharmaceutical Giant Eisai Hit by Ransomware Attack - The Japan News

Pharmaceutical Giant Eisai Hit by Ransomware Attack The Japan News

Alzheimer’s drug co-developed by Eisai approved for use in Japan - 朝日新聞

Alzheimer’s drug co-developed by Eisai approved for use in Japan 朝日新聞

Eisai Limited celebrates opening of new Canadian headquarters - PR Newswire Canada

Eisai Limited celebrates opening of new Canadian headquarters PR Newswire Canada

Results of Eisai Inc. and Epilepsy Foundation National Survey Shed Light on Unmet Needs in Epilepsy Community - MultiVu

Results of Eisai Inc. and Epilepsy Foundation National Survey Shed Light on Unmet Needs in Epilepsy Community MultiVu

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant